Search

Displaying results 2781 - 2790 of 10000 in total
  1. Drug

    AZD3409

    go.drugbank.com/drugs/DB04893
    Experimental

    Phase I trials were initiated January 2003, and were ongoing as of February 2004. As of February 2007 the development of AZD3409 had been discontinued.

  2. Drug

    Chlorophyll B

    go.drugbank.com/drugs/DB04506
    Experimental

    It has the atomic symbol Mg, atomic number 12, and atomic weight 24.31. … (From Dorland, 27th ed)

  3. Drug

    Resorcinol

    go.drugbank.com/drugs/DB11085
    ApprovedInvestigational

    It exerts a keratolytic activity. Resorcinol works by helping to remove hard, scaly, or roughened skin. … It is used as an antiseptic and disinfectant in topical pharmaceutical products in the treatment of skin disorders and infections such as acne, seborrheic dermatitis, eczema, psoriasis, corns, calluses

    Mixtures: BUCO-BLEU KOLLUTUVAR, 15 ML, DG Health Feminine Anti-itchSynonyms: m-Hydroquinone, m-hydroxyphenol
  4. Drug

    Zucapsaicin

    go.drugbank.com/drugs/DB09120
    ApprovedWithdrawn

    Zucapsaicin was approved by the Health Canada in 2010 as topical cream marketed under the brand name Zuacta but currently not FDA-approved. … It is a modulator of transient receptor potential cation channel subfamily V member 1 (TRPV-1), also known as the vanilloid or capsaicin receptor 1, that reduces pain and improves articular functions.

  5. Drug

    Penpulimab

    go.drugbank.com/drugs/DB16747
    ApprovedInvestigational

    Penpulimab is a humanized monoclonal IgG1 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1). The use of an IgG1 backbone - as opposed to an IgG4 backbone as is typical in other anti-PD-1 antibodies like nivoluma...

    Categories: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors
  6. Drug

    Cetyl alcohol

    go.drugbank.com/drugs/DB09494
    Approved

    It can be produced from the reduction of palmitic acid. … It may be contained in cosmetic and personal care products such as shampoos, creams and lotions.

  7. Drug

    Betibeglogene autotemcel

    go.drugbank.com/drugs/DB16900
    ApprovedInvestigational

    [A251770,A251785] Betibeglogene autotemcel was approved by the FDA in August 2022 and is the first ex-vivo lentiviral vector gene therapy available in the U.S. for the treatment of people with β-thalassemia … [A251770] Allogeneic hematopoietic-cell transplantation would be a therapeutic option in patients with β-thalassemia; however, this process is reserved for young children with an HLA-identical sibling

  8. Drug

    Uprifosbuvir

    go.drugbank.com/drugs/DB15206
    Investigational

    C Genotype (GT)1 and GT2 Infection (MK-3682-011)). … Uprifosbuvir is under investigation in clinical trial NCT02332707 (Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis

  9. Drug

    Sipavibart

    go.drugbank.com/drugs/DB21908
    ApprovedInvestigational

    [A274088] It was later approved in Europe in January 2025 and in Canada in March 2025. … [A274098] It works by binding to the SARS-CoV-2 spike protein receptor binding domain (RBD), neutralize the virus and preventing its entry into the host cell.

    Synonyms: Gamma1 heavy chain Homo sapiens (1-455) [VH (Homo sapiens IGHV3-9*01 (94.9%) -(IGHD) -IGHJ1*01 (90.9%) L123>T (120), CDR-IMGT [8.8.18] (26-33.51-58.97-114)) (1-125) -Homo sapiens IGHG1*03, G1m3, nG1m1, Immunoglobulin G1 [242-phenylalanine,243-glutamic acid,260-tyrosine,262-threonine,264-glutamic acid,339-serine], anti-(severe acute respiratory syndrome coronavirus 2 spike glycoprotein receptor-binding
  10. Drug

    Moxetumomab pasudotox

    go.drugbank.com/drugs/DB12688
    ApprovedInvestigational

    [A38864] It was developed by Astra Zeneca and FDA approved on September 13, 2018, after being granted the status of Fast Track, Priority Review and Orphan Drug designations.[L4568]